• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Aids Associated Dementia - Pipeline Review, Q1 2011 - Product Image

Aids Associated Dementia - Pipeline Review, Q1 2011

  • Published: January 2011
  • 19 pages
  • Global Markets Direct

Aids Associated Dementia - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Aids Associated Dementia - Pipeline Review, Q1 2011', provides an overview of the Aids Associated Dementia therapeutic pipeline. This report provides information on the therapeutic development for Aids Associated Dementia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Aids Associated Dementia. 'Aids Associated Dementia - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Aids Associated Dementia.
- A review of the Aids Associated Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Aids Associated Dementia Overview
Therapeutics Development
An Overview of Pipeline Products for Aids Associated Dementia
Aids Associated Dementia Therapeutics under Investigation by Universities/Institutes
Universities/Institutes Involved in Aids Associated Dementia Therapeutics Development
Aids Associated Dementia Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Universities/Institutes
Zidovudine + Didanosine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zidovudine for AIDS Dementia Complex (National Institute of Allergy and Infectious Diseases) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Aids Associated Dementia, 2011
Products under Development for Aids Associated Dementia – Comparative Analysis, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011

List of Figures
Number of Products under Development for Aids Associated Dementia, 2011
Products under Development for Aids Associated Dementia – Comparative Analysis, 2011
Products under Investigation by Universities/Institutes, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Site License The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.
Enterprisewide The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS

Our Clients

Our clients' logos